247 related articles for article (PubMed ID: 35131863)
21. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.
De Luca R; Meraviglia S; Blasi L; Maiorana A; Cicero G
Curr Oncol; 2020 Apr; 27(2):e75-e80. PubMed ID: 32489255
[TBL] [Abstract][Full Text] [Related]
24. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
25. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
27. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab.
Lorentzen CL; Kjeldsen JW; Ehrnrooth E; Andersen MH; Marie Svane I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217243
[TBL] [Abstract][Full Text] [Related]
29. Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report.
Yamaguchi K; Tsuchihashi K; Tsuji K; Kito Y; Tanoue K; Ohmura H; Ito M; Isobe T; Ariyama H; Kusaba H; Akashi K; Baba E
Medicine (Baltimore); 2021 May; 100(19):e25773. PubMed ID: 34106609
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
33. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
34. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
Wang R; Zheng J; Shao X; Ishii Y; Roy A; Bello A; Lee R; Zhang J; Wind-Rotolo M; Feng Y
J Immunother Cancer; 2019 Dec; 7(1):348. PubMed ID: 31829287
[TBL] [Abstract][Full Text] [Related]
35. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of Immunostaining Scoring for Predicting Response to Single-Agent Nivolumab in Patients with Metastatic Renal Cell Carcinoma].
Wakamiya T; Kubo T; Yamashita S; Kohjimoto Y; Torigoe T; Hara I
Hinyokika Kiyo; 2022 Oct; 68(10):311-315. PubMed ID: 36329378
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
Mishima S; Kawazoe A; Nakamura Y; Sasaki A; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Tsuji A; Shitara K
J Immunother Cancer; 2019 Jan; 7(1):24. PubMed ID: 30704511
[TBL] [Abstract][Full Text] [Related]
39. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
40. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL
Cancer Immunol Res; 2016 Sep; 4(9):726-33. PubMed ID: 27491898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
